focus -WSS

focus

author：Wikipedia 2025-09-06 03:54:25 - browse：535

Geoff Martha, CEO of Medtronic Courtesy Medtronic

As one of the largest and oldest medical device companies in the world, Medtronic has a foot in almost every clinical area.

The device maker with a market valuation of nearly $100 billion sells pacemakers, spinal cord stimulators, stents, monitors. Name a device, and they probably make it. The behemoth is ubiquitous in health care, but its size can make innovation sluggish. Medtronic has tried to become more streamlined in recent years — the company announced plans last year to spin off its patient monitoring and respiratory businesses, which Reuters recently reported, citing unnamed sources, may go to the Carlyle Group, a private equity firm.

Still, the device giant is immersed in many different specialties, including diabetes and high blood pressure, where the company has experienced some setbacks. Medtronic has sold old-school insulin pumps since the 1980s and therefore developed robust dosing algorithms, but has never successfully built a tubeless pump. The company plans to buy Korean patch pump maker EOFlow, but EOFlow is enmeshed in a patent battle with Insulet. A federal judge blocked EOFlow from selling its wearable patch pumps earlier this month.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Extreme heat events are a public health emergency

WSS

Dog Aging Project founders on what lies ahead after losing funding

Inaction leaves children at risk from dangerous chemotherapy drug

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

Future doctors need a strong humanities education

Printout prescription drug information shouldn’t go digital

MoonLake credibility takes another hit with mid

leisure time

focus

leisure time

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Maisha Meds is a PBM, but don't call it that

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Ambulance rides for just $100? Advisers want major billing fixes

Wildfire smoke exposes gaps in outdoor worker protections

To bolster infectious disease surveillance, genomics powerhouses team up

The cancer drug shortage isn’t new — and neither are the solutions

TikTok, Instagram influencers need more rules for drug ads

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Dog Aging Project founders on what lies ahead after losing funding

Wikipedia

Medicare solvency divides Republicans at the presidential debate

Abortion clinic in Cancun will cater to Americans

HPV vaccine, cervical cancer study delivers historic results

10 million people disenrolled from Medicaid over past six months

Mass General, Mayo Clinic look to monetize custom

Inaction leaves children at risk from dangerous chemotherapy drug

focus

leisure time

knowledge

hotspot